Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 52-Week High - Time to Buy?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR reached a new 52-week high of $9.23, trading at $8.95, with a volume of 658 shares.
• The company reported $0.16 EPS for the last quarter, exceeding analysts' expectations of $0.14, but its revenue of $672.90 million fell short of the anticipated $719.55 million.
• Shionogi has a market capitalization of $15.07 billion and a low debt-to-equity ratio of 0.01, indicating a strong financial position.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $9.23 and last traded at $8.95, with a volume of 658 shares. The stock had previously closed at $8.95.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 1.0%

The stock's fifty day moving average price is $8.69 and its 200 day moving average price is $8.30. The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The stock has a market cap of $15.07 billion, a PE ratio of 15.43, a PEG ratio of 2.03 and a beta of 0.20.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The firm had revenue of $672.90 million for the quarter, compared to analysts' expectations of $719.55 million. On average, sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.